Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is
* Email Subject: (personalize your message)

Email Content:

Bayer Considers Selling Animal Health Segment


Faced with shareholder opposition, Bayer AG and CEO Walter Baumann are

 considering a number of measures to increase share value.  At issue is the growing number of lawsuits alleging that the herbicide glyphosate marketed as Roundup™ by the recently acquired Monsanto is responsible for non-Hodgkin lymphoma.


The Company has announced layoffs of ten percent of its workforce of 113,000 and will sell some leading brands acquired from Merck and Co. The Animal Health business, strongly dependent on antiparasitics is also under consideration for divestment.